Antiepileptic Drug Discovery

H. Steve White,

H. Steve White

Professor of Pharmacology and Toxicology

University of Utah, Salt Lake City, UT, USA

Search for more papers by this author

H. Steve White,

H. Steve White

Professor of Pharmacology and Toxicology

University of Utah, Salt Lake City, UT, USA

Search for more papers by this author

Book Editor(s):Simon Shorvon MA, MB, BChir, MD, FRCP,

Simon Shorvon MA, MB, BChir, MD, FRCP

Professor in Clinical Neurology Consultant Neurologist

UCL Institute of Neurology, University College London, London, United Kingdom

National Hospital for Neurology and Neurosurgery, London, United Kingdom

Search for more papers by this author

Emilio Perucca MD, PhD, FRCP(Edin),

Emilio Perucca MD, PhD, FRCP(Edin)

Professor of Medical Pharmacology Director

Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Clinical Trial Center, Institute of Neurology IRCCS C Mondino Foundation, Pavia, Italy

Search for more papers by this author

Jerome Engel Jr MD, PhD,

Jerome Engel Jr MD, PhD

Director Professor of Neurology

Jonathan Sinay Distinguished Professor of Neurology, Neurobiology, and Psychiatry and Biobehavioral Sciences, Los Angeles, CA, USA

UCLA Seizure Disorder Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Search for more papers by this author

First published: 22 July 2009

https://doi.org/10.1002/9781444316667.ch6

Citations: 2

Summary

This chapter contains sections titled:

Characteristics of the ideal model system
The current era of antiepileptic drug discovery
Pharmacological profile and potential clinical utility
Recommendations
What is the future of AED discovery and development?
Pharmacoresistant seizure models
Disease modification
Summary
References

Citing Literature

The Treatment of Epilepsy, Third Edition